Evidence map›Paper›PMID 22092282›Full record

ArticleEpilepsia2011

Is there a critical period for mossy fiber sprouting in a mouse model of temporal lobe epilepsy?

Felicia H Lew, Paul S Buckmaster

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Epileptogenesis.Cold Spring Harbor perspectives in medicine · 2015
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Felicia H LewDepartment of Comparative Medicine, Stanford University, Stanford, California 94305, USA.
Paul S Buckmaster
Stanford University · USWashington State University · US

Funding

Ictogenesis in a model of temporal lobe epilepsyR01NS040276 · NINDS · STANFORD UNIVERSITY · PI BUCKMASTER, PAUL S. · 2000 to 2019
$5.8M
Research Opportunities in Comparative MedicineT35OD010989 · OD · STANFORD UNIVERSITY · PI BUCKMASTER, PAUL S. · 2012 to 2022
$565k
RESEARCH OPPORTUNITIES IN COMPARATIVE MEDICINET35RR017188 · NCRR · STANFORD UNIVERSITY · PI BUCKMASTER, PAUL S. · 2002 to 2011
$379k
NCRR NIH HHS T35 RR017188NIH HHS T35 OD010989NINDS NIH HHS R01 NS040276
6 · The paper itself

Abstract

purposeDentate granule cell axon (mossy fiber) sprouting creates an aberrant positive-feedback circuit that might be epileptogenic. Presumably, mossy fiber sprouting is initiated by molecular signals, but it is unclear whether they are expressed transiently or persistently. If transient, there might be a critical period when short preventative treatments could permanently block mossy fiber sprouting. Alternatively, if signals persist, continuous treatment would be necessary. The present study tested whether temporary treatment with rapamycin has long-term effects on mossy fiber sprouting.

methodsMice were treated daily with 1.5 mg/kg rapamycin or vehicle (i.p.) beginning 24 h after pilocarpine-induced status epilepticus. Mice were perfused for anatomic evaluation immediately after 2 months of treatment ("0 delay") or after an additional 6 months without treatment ("6-month delay"). One series of sections was Timm-stained, and an adjacent series was Nissl-stained. Stereologic methods were used to measure the volume of the granule cell layer plus molecular layer and the Timm-positive fraction. Numbers of Nissl-stained hilar neurons were estimated using the optical fractionator method. KEY

findingsAt 0 delay, rapamycin-treated mice had significantly less black Timm staining in the granule cell layer plus molecular layer than vehicle-treated animals. However, by 6-month delay, Timm staining had increased significantly in mice that had been treated with rapamycin. Percentages of the granule cell layer plus molecular layer that were Timm-positive were high and similar in 0 delay vehicle-treated, 6-month delay vehicle-treated, and 6-month delay rapamycin-treated mice. Extent of hilar neuron loss was similar among all groups that experienced status epilepticus and, therefore, was not a confounding factor. Compared to naive controls, average volume of the granule cell layer plus molecular layer was larger in 0 delay vehicle-treated mice. The hypertrophy was partially suppressed in 0 delay rapamycin-treated mice. However, 6-month delay vehicle- and 6-month delay rapamycin-treated animals had similar average volumes of the granule cell layer plus molecular layer that were significantly larger than those of all other groups. SIGNIFICANCE: Status epilepticus-induced mossy fiber sprouting and dentate gyrus hypertrophy were suppressed by systemic treatment with rapamycin but resumed after treatment ceased. These findings suggest that molecular signals that drive mossy fiber sprouting and dentate gyrus hypertrophy might persist for >2 months after status epilepticus in mice. Therefore, prolonged or continuous treatment might be required to permanently suppress mossy fiber sprouting.

Indexed as

Critical Period, PsychologicalAnimalsDisease Models, AnimalEpilepsy, Temporal LobeHippocampusImmunosuppressive AgentsMiceMossy Fibers, HippocampalMuscarinic AgonistsNeuronsPilocarpineSirolimusTime FactorsImmunosuppressive AgentsMuscarinic AgonistsPilocarpineSirolimus

Identifiers

PMID22092282
PMCPMC3233231
OpenAlexW1554321177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.